Sangamo Announces ASGCT 2024


Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients

- Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the six treated patients - The five longest treated patients exhibited elevated α-Gal A activity, ranging from nearly 3-fold to nearly 17-fold above mean normal, up to 15 months as at the